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Abstract
Background: b-lactamase production and porin decrease are the well-recognized mechanisms of acquired ß-lactam
resistance in Klebsiella pneumoniae isolates. However, such mechanisms proved to be absent in K. pneumoniae isolates that
are non susceptible to cefoxitin (FOX) and succeptible to amoxicillin+clavulanic acid in our hospital. Assessing the role of
efflux pumps in this b-lactam phenotype was the aim of this study.
Methodology/Findings: MICs of 9 b-lactams, including cloxacillin (CLX), and other antibiotic families were tested alone and
with an efflux pump inhibitor (EPI), then with both CLX (subinhibitory concentrations) and EPI against 11 unique bacteremia
K. pneumoniae isolates displaying the unusual phenotype, and 2 ATCC strains. CLX and EPI-dose dependent effects were
studied on 4 representatives strains. CLX MICs significantly decreased when tested with EPI. A similar phenomenon was
observed with piperacillin+tazobactam whereas MICs of the other b-lactams significantly decreased only in the presence of
both EPI and CLX. Thus, FOX MICs decreased 128 fold in the K. pneumoniae isolates but also16 fold in ATCC strain.
Restoration of FOX activity was CLX dose-dependent suggesting a competitive relationship between CLX and the other b-
lactams with regard to their efflux. For chloramphenicol, erythromycin and nalidixic acid whose resistance was also due to
efflux, adding CLX to EPI did not increase their activity suggesting differences between the efflux process of these molecules
and that of b-lactams.
Conclusion: This is the first study demonstrating that efflux mechanism plays a key role in the b-lactam susceptibility of
clinical isolates of K. pneumoniae. Such data clearly evidence that the involvement of efflux pumps in ß-lactam resistance is
specially underestimated in clinical isolates.
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Introduction
Klebsiella pneumoniae, a member of Enterobacteriaceae family, is an
important pathogen in both the community and the hospital setting
[1]. Over the last 20 years, attention has particularly been paid to K.
pneumoniae K1 isolates causing pyogenic liver abscesses and also to
multidrug-resistant K. pneumoniae isolates, primarily observed in the
hospital and currently also in the community [1–3].
b-lactamase production and reduced porin levels are the main
mechanisms of ß-lactam resistance reported in K. pneumoniae
isolates [4]. We recently observed clinical isolates with a paradoxal
b-lactam phenotype suggesting mechanisms not linked to b-
lactamase acquisition: these isolates were less susceptible to
cefoxitin and susceptible to both amoxicillin/clavulanic acid and
extended-spectrum cephalosporins. Cefoxitin resistance in entero-
bacterial isolates without chromosomal AmpC b-lactamase
suggests the production of an AmpC-plasmid-mediated enzyme.
This mechanism could not be retained because the isolates were
susceptible to amoxicillin/clavulanic acid which is inconsistent
with a plasmid-mediated-AmpC production [5]. Alternatively, the
b-lactam-resistant phenotype and the chloramphenicol and
nalidixic acid resistance may suggest a modification of the
membrane permeability in the isolates [6]. The final mechanism
which may be involved in cefoxitin resistance is active efflux. Such
a possibility has recently been hypothesized, but not yet
demonstrated [7].
An analysis of the microbiology hospital laboratory database
showed that this unusual b-lactam phenotype was present in
almost 5% of all K. pneumoniae clinical isolates in our hospital for
the last 8 years. These isolates were epidemiologically unrelated,
obtained from various specimens (urine 41%, deep-seated pus and
fluids 20%, blood 14%, drainage fluids 8%, broncho-pulmonary
aspirates 4%, other 13%) and originated from different hospital
wards (surgery 33%, medicine 31%, intensive care units (ICU)
25%, emergency 9%, and obstetrics 2%).
The main purpose of this study was to assess the role of efflux
pumps in the unusual b-lactam resistant phenotype that is
emerging in clinical isolates.
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Results
Molecular typing and b-lactamase content of isolates
A unique RAPD profile was found from each K. pneumoniae
isolate (Table 1). No TEM- and AmpC- encoding genes were
detected in these isolates.
The 3 chromosomal bla gene types previously described in K.
pneumoniae [8] were found in all isolates, the most common type
(n = 8) being blaSHV (Table 1).
Immunodetection of AcrA-TolC components and porins
To investigate a possible alteration of membrane permeability
due to an increase in the major RND efflux pump, AcrAB
[6,9,10], and a decrease in porin production [11], immunodetec-
tion analyses were performed on clinical isoates. Concerning the
efflux mechanism, five (KPBj 1, 3, 5, 9, and 11) of the eleven
isolates expressed AcrA at a level similar to that of the reference
strain ATCC 11296 and six (KPBj 2, 4, 6, 7, 8, and 10) at a higher
level (Figure 1). Regarding TolC, four strains (KPBj 6, 7, 8, and
11) exhibited a higher signal than that of strain ATCC 11296
(Figure 1).
For porin expression, all isolates except for strain KPBj 6,
exhibited a positive signal with variable intensity when the
detection was carried out with the antisera directed against porins
(Figure 2). Similar results were obtained with a specific antibody
directed against the internal loop of enterobacterial porins (data
not shown). In contrast, OmpA was detected in all isolates
(Figure 2).
Antibiotic susceptibility
The K. pneumoniae isolates showed an extended multidrug-
resistance profile according to MICs of the antibiotics tested
(Table 2). Most isolates exhibited a resistance level to chloram-
phenicol, nalidixic acid, amoxicillin, piperacillin and cefoxitin.
MICs of cloxacillin and erythromycin, two antibiotics known to be
non active on Enterobacteriaceae, were extremely high. The absence
Table 1. Clinical and molecular characters of 11 K. pneumoniae clinical isolates less susceptible to cefoxitin and susceptible to
amoxicillin+clavulanic acid.
Strain Sample Isolation date Ward RAPD profile Chromosomal bla gene
KPBj 1 Blood 07/31/2003 Hematology G SHV-1
KPBj 2 Blood 06/05/2004 Digestive surgery D SHV-1
KPBj 3 Blood 11/15/2001 Hepatology F LEN-1
KPBj 4 Blood 11/30/2000 Hepatology ICU C SHV-1
KPBj 5 Blood 06/15/2004 Surgery ICU H SHV-11
KPBj 6 Drainage Fluid 05/29/2005 Hepatology J SHV-1
KPBj 7 Blood 02/03/2005 Hepatology ICU I SHV-1
KPBj 8 Blood 10/08/2001 Digestive ICU E SHV-1
KPBj 9 Blood 08/27/2001 Digestive ICU K SHV-1
KPBj 10 Blood 06/21/2000 Hepatology ICU A LEN-1
KPBj 11 Blood 08/23/2000 Gastro-enterology B OKP-B
ICU: intensive care unit.
doi:10.1371/journal.pone.0004817.t001
Figure 1. Detection of AcrA and TolC in Klebsiella pneumoniae isolates. Top part, immunodetection was carried out with antiserum directed
against denatured AcrA; bottom part, immunodetection was carried out with antiserum directed against denatured TolC porin. WT, E. aerogenes wild
type strain producing normal level of AcrA and TolC; acrA, acrA deleted strain; tolC, tolC deleted strain [16]. a and b indicate the migration of the
molecular weight marker 30 kD and 43 kD, respectively. ATCC, ATCC11296, lanes 1 to 11, strain KPBj 1 to strain KPBj 11.
doi:10.1371/journal.pone.0004817.g001
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of mutations in the quinolone resistance determining region
(QRDR) of GyrA and ParC as well as the absence of qnr genes was
checked in the eleven isolates (data not shown).
We have previously demonstrated that phenylalanine-arginine
ß-naphthylamide (PAßN) is able to block the efflux pumps
involved in antibiotic expel in E. aerogenes and Klebsiella pneumoniae
clinical strains [12,13]. This efflux pump inhibitor is able to restore
partially or totally, depending on the presence of additional
resistance mechanisms, the susceptibility to several antibiotics in
resistant isolates and it can be fruitfully used to detect the presence
of an inhibitor-sensitive efflux in resistant enterobacterial strains
[14–16]. Adding the efflux inhibitor PAßN resulted in a significant
decrease in MICs of some antibiotics to which wild type K.
pneumoniae isolates are susceptible - chloramphenicol, nalidixic
acid, ofloxacin - and also to which K. pneumoniae isolates are
inherently resistant - cloxacillin and erythromycin (Table 2). On
the contrary, the addition of PAßN did not significantly modify
MICs of the ß-lactam molecules tested - amoxicillin alone and
associated with clavulanic acid (an inhibitor of class A b-
lactamases), piperacillin, cefoxitin, ceftazidime, cefepime and
ertapenem, - except for piperacillin associated with tazobactam,
another inhibitor of class A b-lactamases (Table 2).
ß-lactam susceptibility and competitive assays
With the same strains and under the same conditions, we
observed a 4 to 128-fold decrease in cefoxitin MICs tested in the
presence of PAßN when cloxacillin was added at sub-inhibitory
concentrations (1/20 MIC). Such an addition led to no variation
of nalidixic acid MICs tested in the presence of PAßN (Table 3).
The reduction of the MIC for cefoxitin by PAßN was less effective
in strain KPBj 6 which was porin deficient (Table 3).
To characterize the apparent competitive efflux between cefoxitin
and cloxacillin in the presence of PAßN, a cloxacillin dose-effect
experience was carried out (Figure 3). At a cloxacillin concentration
of 0.094 mM, cefoxitin MICs were significantly reduced against all
strains. In contrast, no variation was detected when the competition
assay was carried out with nalidixic acid (Table 4).
To determine a possible concentration threshold for PAßN
effect on cefoxitin MIC in the presence of cloxacillin, a dose assay
was carried out with increasing PAßN concentrations and two
different cloxacillin concentrations. Table 5 indicates a significant
decrease in cefoxitin MICs up to 0.038 mM of PAßN for CLX
concentrations 0.094 and 0.117 mM. This PAßN concentration
threshold was also observed for increasing the nalidixic acid
activity on the same strains (data not shown).
To evaluate the synergic effect conferred by cloxacillin and
PAßN, with regard to cefoxitin activity, differentß-lactam
molecules were tested in the same conditions (Table 6). A synergic
effect was noted with amoxicillin, piperacillin, cefepime, ceftazi-
dime and ertapenem indicating that the antibiotic activity of these
ß-lactams was increased in the presence of PAßN plus cloxacillin.
As for nalidixic acid, no MIC change was observed with
chloramphenicol, ofloxacin and erythromycin when cloxacillin
was added to PAßN (data not shown). Finally, addition of
clavulanic acid to cefoxitin+PAßN with or without cloxacillin did
not modify cefoxitin MICs. On the contrary, addition of clavulanic
acid to the amoxicillin, PAßN and cloxacillin mixture led to a
higher decrease in amoxicillin MICs (Table 7).
Discussion
Various mechanisms of b-lactam resistance have been
described in K. pneumoniae. The most common mechanism
consists of various plasmid-mediated -b-lactamases, the most
recently described being the carbapenemases KPC [17]. Reduced
outer membrane permeability has also been described and
generally in association with plasmid-mediated b-lactamases [4].
If the involvement of efflux activity has been clearly demonstrated
in K. pneumoniae clinical isolates with regard to various antibiotic
families, including chloramphenicol, tetracyclines and quino-
lones, it has never been the case with respect to b-lactam
molecules [12]. We hypothesized that such a mechanism could be
active in a group of K. pneumoniae clinical isolates representing
approximately 5% of K. pneumoniae isolates in our hospital over
the last ten years. This expectation was based on a paradoxal b-
lactam resistant phenotype (reduced susceptibility to cefoxitin and
susceptibility to both amoxicillin+clavulanic acid and extended
spectrum cephalosporins) associated with a conjoint chloram-
phenicol and quinolone resistance.
Figure 2. Detection of porins in Klebsiella pneumoniae isolates. Top part, immunodetection was carried out with antiserum directed against
denatured OmpF porin; bottom part, immunodetection was carried out with antiserum directed against denatured OmpC porin. In the two
incubation assays, antiserum directed against denatured OmpA was used as control. ATCC: ATCC11296; lane 1 to 11, strain KPBj 1 to strain KPBj 11;
OmpF and OmpC illustrate the migration of the E. coli porins in the same conditions (used as internal standards in SDS-PAGE). Arrows and circles
indicate the migration of porins and OmpA, respectively; a, indicates the migration of the molecular weight marker (30 kD).
doi:10.1371/journal.pone.0004817.g002
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Therefore, expression of AcrAB-TolC, two components of the
major pump in the Enterobacteriaceae [9,10] was studied in eleven K.
pneumoniae isolates in comparison with strain ATCC 11296. These
eleven isolates were clonally unrelated strains, belonged to the
different bla gene-based groups of K. pneumoniae and were free of
plasmid-mediated AmpC enzymes [8]. Some isolates produced a
higher AcrAB-TolC signal compared to strain ATCC 11296 as
previously reported in a collection of Turkish multi-drug resistant
isolates [12]. In addition, we found that the production of porins,
immunorelated to OmpC and OmpF porins, was quite similar to
that of strain ATCC 11296 except for one strain, KPBj6, which
exhibited a porin deficient phenotype. The OmpA level indicated
that this strain exhibited a porin deficient profile without a
pleiotropic alteration of membrane proteins [18]. By using PAßN,
a well-known EPI [14,15], we noted that the chloramphenicol,
nalidixic acid, ofloxacin, erythromycin and cloxacillin MICs
decreased substantially. These antibiotics are well-known sub-
strates of efflux pumps but this is the first sound evidence that
cloxacillin is an efflux pump substrate in K. pneumoniae isolates [19].
The addition of sub-inhibitory concentrations of cloxacillin to
PAßN induced a significant restoration of ß-lactam activities in the
pioneer competitive assay developed here. This effect was
observed with the different ß-lactam molecules tested especially
with cefoxitin, amoxicillin, piperacillin and cefepime. No MIC
decrease was observed with the other antibiotic families tested in
the same experimental conditions.
Interestingly, the 16-fold decrease in amoxicillin MIC obtained
in the presence of both cloxacilin and PAbN was doubled when
clavulanic acid which inhibits hydrolytic activity of the K.
pneumoniae chromosomal b-lactamase was added (Table 7). As no
effect of clavulanic acid was detected when it was added to the
association cefoxitin/PAbN, this indicates that clavulanic acid is
not a pump substrate or presents a weak affinity for efflux pump
sites compared to cloxacillin added to the same association
(cefoxitin/PAßN). Therefore, all these findings strongly suggest
that the innate amoxicillin resistance observed in K. pneumoniae
would be due to amoxicillin efflux for a part and amoxicillin
Figure 3. MICs of cefoxitin for two K. pneumoniae isolates (KpBj
7 and 9) and strain ATCC 11296 measured in the presence of
efflux inhibitor PAbN (0.096 mM) and increased concentrations
of cloxacillin (CLX). MIC percent (MIC%) represents the decrease in
cefoxitin MIC in the presence of different CLX concentrations (plotted as
CLX (mM)) compared with MIC measured without PAßN and CLX.
doi:10.1371/journal.pone.0004817.g003
Table 4. Cloxacillin dose-effect on MICs of nalidixic acid tested alone and with PAbN towards 4 representative K. pneumoniae
strains.
Strain MIC (mg/L) of NAL
Alone +PAßN* +PAbN*+CLX [mM]
0.045 0.06 0.078 0.096 0.117 0.156 0.234
ATCC 11296 16 1 1 1 1 1 1 1 1
KPBj 6 2048 4 4 4 4 4 8 8 8
KPBj 7 128 4 4 4 4 4 4 4 4
KPBj 9 64 4 4 4 4 4 4 4 4
NAL: nalidixic acid, *: 0.096 mM (50 mg/L), CLX: cloxacillin.
doi:10.1371/journal.pone.0004817.t004
Table 3. MICs of cefoxitin and nalidixic acid tested alone and with inhibitor efflux (PAbN) and sub-inhibitory concentrations of
cloxacillin towards 4 representative K. pneumoniae strains.
Strain MIC mg/L
FOX NAL CLX FOX+ NAL+ CLX+ FOX+ NAL+ FOX+ NAL+
PAbN* PAbN* PAbN* CLX¤ CLX¤ CLX¤+PAbN* CLX¤+PAbN*
ATCC 11296 8 16 1024 8 1 64 4 16 0.25 1
KPBj 6 64 2048 2048 64 4 128 32 1024 8 8
KPBj 7 64 128 2048 64 4 256 64/32 64 0.5 4
KPBj 9 128 64 1024 64 4 64 64 128 1 4
FOX: cefoxitin, NAL: nalidixic acid, CLX: cloxacillin, *: 0.096 mM (50 mg/L), ¤: 1/20 CLX MIC.
doi:10.1371/journal.pone.0004817.t003
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hydrolysis for the other part. Another balance seems to exist with
tazobactam, which is another inhibitor of class A-enzyme.
Indeed, adding PAßN to the association piperacillin/tazobactam
resulted in a significant decrease in MIC of this association while
no increase in susceptibility was noted when PAßN was added to
piperacillin alone. This finding strongly suggests that tazobactam
is an efflux substrate that exhibitss a reduced affinity for the
pump sites compared to cloxacillin. Interestingly, the study of
ligand-transporter interaction carried out with purified AcrB has
reported the presence of affinity sites exhibiting different affinity
Table 6. MICs of b-lactam molecules tested alone and with fixed concentrations of PAbN and cloxacillin towards 4 representative
K. pneumoniae strains.
Strain Mol. added MIC mg/L
AMX PIP FEP CAZ ERT
PAbN* 2 + + 2 + + 2 + + 2 + + 2 + +
CLX¤ 2 2 + 2 2 + 2 2 + 2 2 + 2 2 +
ATCC 11296 256 128 16 32 32 0.125 0.125 0.125 0.0015 1 0.25 0.125 0.015 0.015 0.007
KBPj 6 1024 1024 256 64 64 2 0.5 0.5 0.125 0.5 0.5 0.125 0.25 0.25 0.06
KPBj 7 512 512 32 64 64 0.25 0.5 0.5 0.06 1 0.5 0.06 0.06 0.06 0.007
KPBj 9 2048 2048 64 128 128 0.5 1 0.5 0.03 1 0.5 0.125 0.25 0.25 0.03
Mol: molecule, *: 0.096 mM, ¤: 0.117 mM, CLX: cloxacillin, AMX: amoxicillin, PIP: piperacillin, FEP: cefepime, CAZ: ceftazidime, ERT: ertapenem.
doi:10.1371/journal.pone.0004817.t006
Table 5. PAßN dose-effect on MICs of cefoxitin tested alone and with two different sub-inhibitory concentrations of cloxacillin
towards 4 representative K. pneumoniae strains.
MIC (mg/L) of FOX
Strains Alone +CLX* +0.094 mM CLX+PAßN [mM (mg/L)] +0.117 mM CLX+PAßN [mM (mg/L)]
0.009
(5)
0.019
(10)
0.038
(20)
0.058
(30)
0.077
(40)
0.096
(50)
0.009
(5)
0.019
(10)
0.038
(20)
0.058
(30)
0.077
(40)
0.096
(50)
ATCC
11296
8 8 8 8 4 1 1 1 8 8 2 0.5 0.25 0.25
KPBj 6 64 64 64 32 16 16 8 8 32 32 16 8 8 8
KPBj 7 64 64 64 32 8 2 2 2 32 32 4 1 0.5 0.5
KPBj 9 128 64 128 64 16 8 4 4 64 64 4 2 1 1
*, same results were obtained in the presence of 0.094 mM or 0.117 mM of CLX.
FOX: cefoxitin, CLX: cloxacillin.
doi:10.1371/journal.pone.0004817.t005
Table 7. MICs of cefoxitin and amoxicillin tested alone and with PAbN, cloxacillin and clavulanic acid towards 4 representative K.
pneumoniae strains.
Strain Mol. added MIC mg/L
FOX AMX
PAbN* 2 + + + + + + 2 + 2 + + +
CLX¤ 2 2 + 2 2 + + 2 2 2 2 + +
CLA 2D 2 2 2 + 2 + 2 2 2 + + 2 +
CLA 20{ 2 2 2 2 + 2 + 2 2 2 2 2 2
ATCC 11296 8 8 0.25 8 8 0.5 0.5 256 128 2 2 16 0.5
KPBj 6 64 64 8 32 16 16 8 1024 1024 4 4 256 8
KPBj 7 64 32 0.5 32 16 1 1 512 512 8 8 32 4
KPBj 9 128 64 1 64 64 2 1 2048 2048 4 4 64 4
Mol: molecule, FOX: cefoxitin, AMX: amoxicillin, CLX: cloxacillin, CLA: clavulanic acid, *: 0.096 mM, ¤: 0.117 mM, D: 2 mg/L, {: 20 mg/L.
doi:10.1371/journal.pone.0004817.t007
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constants (KD values from 5.5 to 74.1 mM) for various substrates
[20].
The restoration of ß-lactam activity observed in the presence of
both EPI and cloxacillin showed that cloxacillin may act as a direct
competitor for ß-lactam efflux. This competitive effect was obtained
at low concentration of cloxacillin compared to the cloxacillin MIC
found for the K. pneumoniae isolates and with the low amounts of
PAßN classically used to inhibit the efflux of chloramphenicol and
quinolones [12]. This increase in ß-lactam susceptibility, described
even in ATCC strain, demonstrates the existence of a ß-lactam efflux
pump expressed at low level in K. pneumoniae. Interestingly, we
observed a noticeable PAßN-susceptible efflux of cloxacillin in strains
KPBj 1 and ATCC strain in contrast to the PAßN-susceptible efflux
of chloramphenicol. In addition, a PAßN-susceptible erythromycin
efflux was also noted and we have previously demonstrated that
macrolide efflux should be independent to AcrAB system [21].
Therefore, as the susceptibility increase does not necessarily require
an AcrAB-TolC over expression, two hypotheses may be proposed
to explain our findings:
1- The level of AcrAB-TolC expressed in the K. pneumoniae isolates
is sufficient to maintain the ß-lactam intracellular concentration
under the threshold required for antibacterial activity. If it was the
case, due to the presence of different affinity sites located inside the
AcrB pump, as mentioned during previous co-crystalization analyses
and as suggested by the recent proposed model, it would be possible
that the gain generated by conjoint addition of EPI and cloxacillin be
due to a synergistic effect [22,23]. In the same time, EPI would
induce a steric hindrance inside the general cavity and cloxacillin
would generate a competitive occupation of a ß-lactam affinity site
[22]. This attractive hypothesis fits well with the AcrB vestibule entry
located at the periplasmic surface of inner membrane, the report
mentioning the respective location of PAßN and other ligands inside
AcrB cavities, and with the idea of a flux competition conferred by a
saturation of pump channel associated with occupation of specific
sites exhibiting high affinity for specific drugs (ß-lactam such as
cloxacillin) which cannot modify the susceptibility of other antibiotic
classes (e.g. quinolone, macrolide) [22]. Recent competition exper-
iments performed with the purified AcrB pump and various ligands
have demonstrated that erythromycin is not able to inhibit the
binding of other molecules suggesting that different families of drugs
recognize different non-overlapping sites [20]. Moreover, Elkins and
Mullis have demonstrated the presence of substrate hierarchy or
selectivity during competitive experiences using macrolide or steroid
uptake, competition occurring inside a same structural class in E. coli
[24].
Regarding this hypothesis it is worthwhile of note that the
binding of substrates to affinity sites located inside AcrB in
Haemophilus influenzae induces noticeable conformational change
altering the reactivity of specific residues [25]. In addition, the
functional rotation mechanism evidenced for the multidrug efflux
pump AcrB may also support this first hypothesis by the existence
of three independent efflux sites acting step by step and capable to
accept different substrates due to the site flexibility during the loose
state [23].
2- The second hypothesis is that there are two pumps acting in
these isolates or that selected mutations, in the efflux pump, may
increase the selectivity for some substrates over other transported
molecules in clinical isolates. In recent reports, several teams have
mentioned the activity of pumps, different from AcrAB, which
would be involved in antibiotic expel [for a review see 10,19]. In
this case, the respective affinity for the various substrates, ß-
lactams, quinolones and macrolides, could be different as
previously observed with the Mex pump family in P. aeruginosa
[26]. Moreover, this difference also would concern PAßN for
which some variations have been reported concerning the range of
its efflux inhibitory spectrum [14,27]. In this condition, two pumps
or a selective-modified one would be functioning. In the first case,
one expels quinolone, macrolides, PAßN, and also ß-lactams but
with a lower efficiency/selectivity, the other having a high affinity
for ß-lactam and a reduced affinity for PAßN. In the second case,
the affinity for specific antibiotics being increased in the modified
pump, the efflux blockage needs a competitive substrate that
belongs to the same antibiotic structural class to be effective. This
may reflect the variation in the immunodetected signal of efflux
pump components obtained with our antibodies. As mentioned in
the two hypotheses, the presence of PAßN is necessary in addition
to the efficient competitor (CLX). This may support the presence
of separate and discrete pockets inside the efflux channel which
exhibit different affinity constants and which recognize various
molecules (e.g. PAßN and CLX). In the absence of CLX, the
PAßN affinity is not sufficient to impair FOX recognition, and in
the absence of PAßN the corresponding non-specific site may
accommodate FOX molecules with a reduced but significant
efficiency to expel the drug (Figure 4).
Whatever the number and the selectivity of pump acting in
these isolates, it is clearly demonstrated that efflux plays a key role
in the ß-lactam uptake and susceptibility in K. pneumoniae. It is also
clear that this role has been largely underestimated if we take into
account the involvement of efflux in the acquisition of additional
mechanisms of resistance as shown in Salmonella sp. and
Campylobacter sp. [28,29]. In addition, this study may explain
previous reports describing a ß-lactam resistance level without
consistent description of enzyme production or porin alteration
and evoking a possible role of efflux in K. pneumonia [7]. From the
pioneer studies of H. Nikaido on the in vitro efflux pumps activities
and the model of efflux mechanism as vacuuming the periplasm,
this study clearly highlights the clinical impact of efflux activity in
ß-lactam susceptibility for the first time in Enterobacteriaceae
[10,30,31]. This result is especially important with regard to the
previous observations showing that some ß-lactams stimulate the
expression of efflux pumps in infecting enterobacteria [32]. In vitro
experiments have documented the role of mar cascade in the
selection of resistant strains expressing efflux pumps under ß-
lactam stress [32]. The emergence of K. pneumoniae isolates
exhibiting a ß-lactam efflux, associated or not with a failure of
porin expression, directly involved in antibiotic resistance is a
predicted event. This may occur in different types of infections and
we described here this bacterial strategy which concerns a number
of isolates collected during a recent period and which exhibited a
specific antibiotic resistance pattern.
This is the first time that the efflux involvement is clearly
demonstrated to impact on clinical ß-lactam susceptibility in
Enterobacteriaceae. This effect observed in our isolates is especially
worrying due to the multiple factors (genetic and chemical) that
activate the expression of efflux mechanisms in bacteria belonging
to natural flora or possibly involved in nosocomial pathogens.
Materials and Methods
Bacterial strains and clinical data
Eleven K. pneumoniae isolates collected over a period of 5 years
(2000–2005) in Beaujon hospital were studied. Ten of them had
been isolated from blood and one from drainage fluid (Table 1).
The majority of the patients infected by these isolates had
hepatogastroenterological diseases (9/11) and 6 were hospital-
ized in ICU when the K. pneumoniae infection occurred. K.
pneumoniae strains ATCC 11296 and 138831 were used as
reference strains.
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Molecular epidemiology typing
The eleven isolates were typed by Random Amplified
Polymorphism DNA (RAPD) [33].
ß-lactamase determination
bla genes encoding AmpC and TEM ß-lactamases were
identified by PCR [34]. The chromosomal bla gene of the eleven
isolates were amplified and then sequenced as described [8].
Immunocharacterisation of membrane transporters
Exponential-phase bacteria in LB broth were pelleted and
solubilized in boiling buffer at 96uC [12]. Total cell protein
(OD600= 0.01 corresponding to equal protein per well) was
loaded onto a SDS-polyacrylamide gel (10% polyacrylamide,
0.1% SDS) [12,18,35]. Proteins were electro-transferred onto
nitrocellulose membranes in transfer buffer. An initial saturating
step was performed overnight at 4uC with Tris-buffered sodium
(TBS: 50 mM Tris-HCl pH 8.0, 150 mM NaCl) containing
skimmed milk powder (10%). The nitrocellulose sheets were then
incubated in TBS containing skimmed milk powder (5%) and
Triton X-100 (0.2%) for 2 h at room temperature in the presence
of polyclonal antibodies (1:2,000 dilution) directed against
denatured OmpF porin, denatured OmpC porin, OmpA [18] or
against denatured AcrA or TolC [12,16]. It is important to
mention that our previous studies have demonstrated a strong
cross-immunoreactivity between E. coli and K. pneumoniae porins
[12,13] due to the conservations of common antigenic regions
[35]. Polyclonal antibodies directed against E. coli OmpC and
OmpF porins have been used for the detection of expressed porins
in the various K. pneumoniae strains. The detection of antigen-
antibody complexes was performed with alkaline phosphatase
conjugated AffinitiPure goat anti-rabbit IgG antibodies [18].
Antibiotic susceptibility tests
Bacteria were grown in Luria–Bertani (LB) or Mueller–Hinton
(MH) broth at 37 C. Susceptibility to amoxicillin (SigmaH),
amoxicillin+clavulanic acid (Glaxo SmithKline) piperacillin (Sa-
nofi AventisH), piperacillin+tazobactam (WyethH), cefoxitin (Sig-
maH), ceftazidime (SigmaH), cefepime (SigmaH), ertapenem
(MSDH), cloxacillin (Astellas Pharma), chloramphenicol (SigmaH),
nalidixic acid (SigmaH), ofloxacin (SigmaH), and erythromycin
(Fluka BiochemikaH) was determined by broth dilution method, as
previously described [18,36]. Minimal inhibitory concentrations
(MICs) were determined with an inoculum of 106 CFU in 1 mL of
Figure 4. Scheme of the selective efflux of ß-lactammolecules and the effect of various molecules. A: the AcrAB-TolC efflux pump. B: the
FOX efflux. C: the effect of PAßN on FOX efflux. D: the effect of PAßN+CLX on FOX efflux. OM, outer membrane; P, periplasmic space; IM, inner
membrane; PBP, penicillin binding protein (ß-lactam target). Cloxacillin (CLX) and cefoxitin (FOX) are represented by black squares or black circles
respectively; and grey triangles represent the PAßN. Black straight arrows represent the drug penetration through the outer membrane and the black
curved lines represent the drug efflux through the efflux pumps. Bold and dotted curved lines indicated the high and low level of FOX efflux
respectively. Empty circles and triangles represent the ß-lactam selective sites and the non-selective sites, respectively. PAßN is able to bind to the
non-selective site located inside the pump cavity and at a lesser extent (due to affinity) to the ß-lactam site. In the presence of ß-lactam (CLX or FOX),
the ß-lactam site is preferentially occupied by the ß-lactam molecules. For clarity reasons, only the first hypothesis was presented. For the second
hypothesis (two pumps), the different drug affinity sites (non-selective and ß-lactam selective sites) may be distributed in the two efflux pumps
acting in the same time in resistant strains.
doi:10.1371/journal.pone.0004817.g004
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MH broth containing two-fold serial dilutions of each antibiotic.
Isolates were classified as susceptible, intermediately susceptible or
resistant to the antibiotics tested according to the Antibiogram
Committee of the French Society for Microbiology (http://www.
sfm.asso.fr).
The efflux pump inhibitor (EPI) phenylalanine arginine ß-
naphthylamide (PAßN) was used as previously reported: MICs of
each antibiotic were determined in the presence of PAßN [36]. To
evaluate a possible role of efflux in the ß-lactam activity, we
developed an in vitro assay using different conditions: ß-lactam, ß-
lactam+EPI, ß-lactam+EPI+sub-inhibitory concentration of clox-
acillin, ß-lactam+EPI+clavulanic acid, and ß-lactam+EPI+sub-
inhibitory concentration of cloxacillin+clavulanic acid on four K.
pneumoniae strains (ATCC 11296, KPBj 6, KPBj 7 and KPBj 9).
Nalidixic acid belonging to another structural antibiotic family was
used as internal standard. The results were scored after 18 h at
37uC and were expressed as MICs. The MICs for PAßN were
256–512 mg/L in the various K. pneumoniae isolates.
Plasmid- and GyrA/ParC-mediated resistance to
quinolones
Plasmid- and chromosome-encoded quinolone resistance deter-
minants (qnr A, B and S, gyrA and parC genes) were studied [37,38].
Acknowledgments
We thank D. O’Callaghan, J.M. Bolla, J. Chevalier, and A. Davin-Regli for
fruitful discussion. We thank A. Seassau for the preliminary studies of
antibiotic susceptibilities. We thank Dr G Jacoby and Dr E Cambau for
providing us with strains harbouring plasmid-mediated qnrA, B and S genes.
Author Contributions
Conceived and designed the experiments: JMP JPL MHNC. Performed
the experiments: JPL VLG EM FB LN. Analyzed the data: JMP JPL FB
MHNC. Contributed reagents/materials/analysis tools: VLG EM FB LN.
Wrote the paper: JMP MHNC. Critically revised the paper: JPL. Revised
the paper: VLG.
References
1. Keynan Y, Rubinstein E (2007) The changing face of Klebsiella pneumoniae
infections in the community. Int J Antimicrob Agents 30: 385–9.
2. Fang C, Lai S, Yi W, Hsueh P, Liu K, et al. (2007) Klebsiella pneumoniae genotype
K1: an emerging pathogen that causes septic ocular or central nervous system
complications from pyogenic liver absecess. Clin Infect Dis 45: 284–93.
3. Su SC, Siu LK, Ma L, Yeh KM, Fung CP, et al. (2008) Community-acquired
liver abscess caused by serotype K1 Klebsiella pneumoniae with CTX-M-15-type
extended-spectrum ß-lactamase. Antimicrob Agents Chemother 52: 804–5.
4. Jacoby GA, Mills DM, Chow N (2004) Role of ß-lactamases and porins in
resistance to ertapenem and other ß-lactams in Klebsiella pneumoniae. Antimicrob
Agents Chemother 48: 3203–6.
5. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for
ß-lactamases and its correlation with molecular structure. Antimicrob Agents
Chemother 39: 1211–33.
6. Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, et al. (2008)
Membrane permeability and regulation of drug ‘‘influx and efflux’’ in
enterobacterial pathogens. Curr Drug Targets 9: 750–9.
7. Gruteke P, Goessens W, Gils J, Peerbooms P, Lemmens-den Toom N, et al.
(2003) Patterns of resistance associated with integrons, the extended-spectrum ß-
lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae
causing a nococomial outbreak. J Clin Microbiol 41: 1161–6.
8. Haeggman S, Lofdahl S, Paauw A, Verhoef J, Brisse S (2004) Diversity and
evolution of the class A chromosomal ß-lactamase gene in Klebsiella pneumoniae.
Antimicrob Agents Chemother 48: 2400–8.
9. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Che-
mother 56: 20–51.
10. Li XZ, Nikaido H (2004) Efflux-mediated drug resistance in bacteria. Drugs 64:
159–204.
11. Page`s J-M, James CE, Winterhalter M (2008) The porin and the permeating
antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev
Microbiol 6: 893–903.
12. Hasdemir UO, Chevalier J, Nordmann P, Page`s J-M (2004) Detection and
prevalence of active drug efflux mechanism in various multidrug-resistant
Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 42: 2701–6.
13. Chevalier J, Page`s J-M, Eyraud A, Malle´a M (2000) Membrane permability
modifications are involved in antibiotic resistance in Klebsiella pneumoniae.
Biochem Biophys Res Commun 274: 496–99.
14. Lomovskaya O, Bostian KA (2006) Practical applications and feasibility of efflux
pump inhibitors in the clinic–a vision for applied use. Biochem Pharmacol 71:
910–18.
15. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Page`s J-M (2007)
Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response
strategy. J Antimicrob Chemother 59: 1223–29.
16. Pradel E, Page`s J-M (2002) The AcrAB-TolC efflux pump contributes to
multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob
Agents Chemother 46: 2640–43.
17. Perez F, Endimiani A, Hujer KM, Bonomo RA (2007) The continuing challenge
of ESBLs. Curr Opin Pharmacol 7: 459–69.
18. Malle´a M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, et al. (1998) Porin
alteration and active efflux: two in vivo drug resistance strategies used by
Enterobacter aerogenes. Microbiology 144: 3003–9.
19. Piddock LJ (2006) Multidrug-resistance efflux pumps - not just for resistance. Nat
Rev Microb 4: 629–36.
20. Su CC, Nikaido H, Yu EW (2005) Ligand-transporter interaction in the AcrB
multigrug efflux pump determined by fluorescence polarization assay. FEBS lett
581: 4972–6.
21. Chollet R, Chevalier J, Bryskier A, Page`s J-M (2004) The AcrAB-TolC pump is
involved in macrolide resistance but not in telitrhomycin efflux in Enterobacter
aerogenes and Escherichia coli. Antimicrob Agents Chemother 48: 3621–4.
22. Yu EW, Aires JR, McDermott G, Nikaido H (2005) A periplasmic drug-binding
site of the AcrB multidrug efflux pump: a crystallographic and site-directed
mutagenesis study. J Bacteriol 187: 6804–15.
23. Seeger MA, Von Ballmoos C, Eicher T, Brandstatter L, Verrey F, et al. (2008)
Engineered disulfide bonds support the functional rotation mechanism of
multidrug efflux pump AcrB. Nat Struct Mol Biol 15: 199–205.
24. Elkins CA, Mullis LB (2007) Substrate competition studies using whole-cell
accumulation assays with the major tripartite multidrug efflux pumps of
Escherichia coli. Antimicrob Agents Chemother 51: 923–9.
25. Dastidar V, Mao W, Lomovskaya O, Zgurskaya HI (2007) Drug-induced
conformational changes in multidrug efflux transporter AcrB from Haemophilus
influenzae. J Bacteriol 189: 5550–8.
26. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, et al.
(2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the
new millenium. Clin Microbiol Infect 13: 560–78.
27. Page`s J-M, Amaral L (2009) Mechanisms of drug efflux and strategies to combat
them: challenging the efflux pump of Gram negative bacteria. Bioch Biophys
Acta - Proteins and Proteomics. in press.
28. Ricci V, Tzakas P, Buckley A, Piddock LJ (2006) Ciprofloxacin-resistant
Salmonella enterica serovar Typhimurium strains are difficult to select in the
absence of AcrB and TolC. Antimicrob Agents Chemother 50: 38–42.
29. Yan M, Sahin O, Lin J, Zhang Q (2006) Role of the CmeABC efflux pump in
the emergence of fluoroquinolone-resistance Campylobacter under selection
pressure. J Antimicrob Chemother 58: 1154–9.
30. Elkins CA, Nikaido H (2003) 3D structure of AcrB: the archetypal multidrug
efflux transporter of Escherichia coli likely captures substrates from periplasm.
Drug Resist Updat 6: 9–13.
31. Lomovskaya O, Totrov M (2005) Vacuuming the periplasm. J Bacteriol 187:
1879–83.
32. Bornet C, Chollet R, Malle´a M, Chevalier J, Davin-Regli A, et al. (2003)
Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes.
Biochem Biophys Res Commun 301: 985–90.
33. Gori A, Espinasse F, Deplano A, Nonhoff C, Nicolas MH, et al. (1996)
Comparison of pulsed-field gel electrophoresis and randomly amplified DNA
polymorphism analysis for typing extended-spectrum-ß-lactamase-producing
Klebsiella pneumoniae. J Clin Microbiol 34: 2448–53.
34. Armand-Lefe`vre L, Leflon-Guibout V, Bredin J, Barguellil F, Amor A, et al.
(2003) Imipenem resitance in Salmonella enterica serovar Wien related to porin loss
and CMY-4 ß-lactamase production. Antimicrob Agents Chemother 47:
1165–8.
35. Simonet V, Malle´a M, Fourel D, Bolla JM, Page`s J-M (1996) Crucial domains
are conserved in Enterobacteriaceae porins. FEMS Microbiol Lett 136: 91–7.
36. Chevalier J, Mulfinger C, Garnotel E, Nicolas P, Davin-Regli A, Page`s J-M
(2008) Identification and evolution of drug efflux pump in clinical Enterobacter
aerogenes strains isolated in 1995 and 2003. PloS ONE 3(9): e3203.
37. Cattoir V, Poirel L, Rotimi V, Soussy C-J, Nordmann P (2007) Multiplex PCR
for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-
producing enterobacterial isolates. J Antimicrob Chemother 60: 394–7.
38. Leflon-Guibout V, Jurand C, Bonacorsi S, Espinasse F, Guelfi M-C, et al. (2004)
Emergence and spread of three clonally related virulent isolates of CTX-M-15-
producing Escherichia coli with variable resistance to aminoglycosides and
tetracycline in a French geriatric hospital. Antimicrob Agents Chemother 48:
3736–42.
Efflux Pump and b-Lactam
PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4817
